News
BIO
--
0.00%
--
Most likely large-cap and small-cap merger candidates -BofA
BofA Securities screened for stocks with the the characteristics most likely to attract suitors, both in the large- and small-cap universes. For S&P 500 (SP500) (SPY) targets, BofA: Screens based
Seekingalpha · 05/15 15:42
BofA's Buy the Dip Screens: bear market rally stocks and beaten-down tech names
BofA strategists have names for investors looking to put cash back to work after the 2022 selloff. The equity strategy teams highlighted two Buy the Dip screens this week. Beaten-down
Seekingalpha · 05/12 12:56
Estimating The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
How far off is Bio-Rad Laboratories, Inc. ( NYSE:BIO ) from its intrinsic value? Using the most recent financial data...
Simply Wall St. · 05/05 15:24
Research Alert: CFRA Keeps Buy Opinion On Shares Of Bio-rad Laboratories Inc.
MT Newswires · 05/02 17:11
5 Value Stocks To Watch In The Healthcare Sector
What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most like...
Benzinga · 05/02 15:04
Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Up
Bio-Rad's (BIO) first-quarter 2022 revenues decline year over year due to lower COVID-related demand.
Zacks · 04/29 14:31
BRIEF-Bio-Rad Reports First-Quarter 2022 Financial Results
reuters.com · 04/28 22:19
Bio-Rad Laboratories (BIO) Surpasses Q1 Earnings and Revenue Estimates
Bio-Rad (BIO) delivered earnings and revenue surprises of 76.43% and 3.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 04/28 21:45
Recap: Bio-Rad Laboratories Q1 Earnings
Bio-Rad Laboratories (NYSE:BIO) reported its Q1 earnings results on Thursday, April 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Benzinga · 04/28 21:05
Bio-Rad Labs Non-GAAP EPS of $4.94 beats by $1.83, revenue of $700.1M beats by $22.1M
Bio-Rad Labs press release (NYSE:BIO): Q1 Non-GAAP EPS of $4.94 beats by $1.83. Revenue of $700.1M (-3.7% Y/Y) beats by $22.1M. COVID-related revenue was approximately $45 million in the first
Seekingalpha · 04/28 20:43
Bio-Rad Laboratories Q1 EPS $4.94 Beats $3.40 Estimate, Sales $700.06M Beat $675.10M Estimate
Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $4.94 per share which beat the analyst consensus estimate of $3.40 by 45.29 percent. This is a 5.18 percent decrease over earnings of $5.21 per share from
Benzinga · 04/28 20:24
Bio-Rad Laboratories Q1 Non-GAAP EPS, Revenue Decline; Maintains 2022 Outlook
MT Newswires · 04/28 17:48
-- Earnings Flash (BIO) BIO-RAD LABORATORIES Reports Q1 EPS $4.94, vs. Street Est of $3.23
MT Newswires · 04/28 16:32
Bio-Rad Labs Q1 2022 Earnings Preview
Bio-Rad Labs (BIO) is scheduled to announce Q1 earnings results on Thursday, April 28th, after market close. The consensus EPS Estimate is $3.11 (-40.3% Y/Y) and the consensus Revenue Estimate
Seekingalpha · 04/27 21:45
Medical Products Stocks' Earnings on Apr 28: TMO, BIO & More
Medical Products companies' results are likely to reflect a rebound in the base business. Let's see how TMO, BIO, LH and RMD fare this time.
Zacks · 04/27 14:52
Bio-Rad (BIO) to Report Q1 Earnings: What's in the Cards?
Robust uptake of dPCR products and a rebound in routine testing are likely to have contributed to Bio-Rad's (BIO) first-quarter top line.
Zacks · 04/25 13:02
Top Healthcare Stocks for May 2022
These are the healthcare stocks with the best value, fastest growth, and most momentum for May 2022.
Investopedia · 04/21 21:17
Here's Why You Should Retain Bio-Rad (BIO) Stock For Now
Investors are optimistic about Bio-Rad (BIO) owing to a recovery in most of its key global markets as well as an uptick in demand for COVID-related products.
Zacks · 04/19 14:19
Illumina (ILMN) Launches Genomic Solution Hub in Brazil
Illumina's (ILMN) customers and partners in Brazil currently span basic research, applied markets to clinical labs and healthcare institutions.
Zacks · 04/13 14:10
10 Biotech Stocks to Buy Today According to Ken Fisher
In this piece, we will take a look at the ten biotechnology stocks to buy according to Ken Fisher’s Fisher Asset Management. If you want to skip the details about the billionaire hedge fund executive and simply want to learn about the top five stocks in th...
Insider Monkey · 04/13 13:09
Webull provides a variety of real-time BIO stock news. You can receive the latest news about Bio Rad Labs Inc through multiple platforms. This information may help you make smarter investment decisions.
About BIO
Bio-Rad Laboratories, Inc. manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate chemical and biological materials and to identify, analyze and purify their components. The Company operates through two segments: Life Science and Clinical Diagnostics. Life Science segment markets and develops, manufactures and markets approximately 6,000 reagents, apparatus and laboratory instruments. Its products are used in research techniques, biopharmaceutical production processes and food testing regimes. Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market.